| scholarly article | Q13442814 |
| P2093 | author name string | Lijuan Wang | |
| Fengyuan Che | |||
| Xueyuan Heng | |||
| Lanlan Zang | |||
| Shukkoor Muhammed Kondengaden | |||
| P2860 | cites work | A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. | Q52593922 |
| Composition and Function of Mammalian SWI/SNF Chromatin Remodeling Complexes in Human Disease. | Q52681632 | ||
| Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression. | Q52715991 | ||
| Mutation of HELLS, a chromatin remodeling gene, gastric and colorectal cancers. | Q54187067 | ||
| Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients. | Q54222671 | ||
| Ionizing radiation-inducible miR-30e promotes glioma cell invasion through EGFR stabilization by directly targeting CBL-B. | Q54289713 | ||
| Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. | Q54517221 | ||
| Immunotherapy With Human Gamma Delta T Cells-Synergistic Potential of Epigenetic Drugs? | Q55030400 | ||
| Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma. | Q55456885 | ||
| miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2. | Q55460959 | ||
| MiR-18a regulates the proliferation, migration and invasion of human glioblastoma cell by targeting neogenin. | Q55461065 | ||
| MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. | Q55462882 | ||
| Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia. | Q64915559 | ||
| Most methylation-susceptible DNA sequences in human embryonic stem cells undergo a change in conformation or flexibility upon methylation | Q85977394 | ||
| DNA methylation patterns and epigenetic memory | Q22065780 | ||
| Functional analysis of the subunits of the chromatin assembly factor RSF | Q24322794 | ||
| Histone deacetylases (HDACs): characterization of the classical HDAC family | Q24535587 | ||
| Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma | Q24612429 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
| Visualizing epigenetics: current advances and advantages in HDAC PET imaging techniques | Q26862755 | ||
| Gene methylation in gastric cancer | Q26991766 | ||
| SWI/SNF chromatin remodeling complexes and cancer | Q26998657 | ||
| Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294 | Q27653816 | ||
| Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents | Q27777800 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma | Q27851550 | ||
| EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. | Q48945472 | ||
| Concerted action of histone methyltransferases G9a and PRMT-1 regulates PGC-1α-RIG-I axis in IFNγ treated glioma cells | Q49056915 | ||
| Mutation analysis of DKK1 and in vivo evidence of predominant p53-independent DKK1 function in gliomas | Q49116936 | ||
| Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. | Q50042687 | ||
| Models of Epigenetic Age Capture Patterns of DNA Methylation in Glioma Associated with Molecular Subtype, Survival, and Recurrence. | Q50047153 | ||
| Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma. | Q50220589 | ||
| Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. | Q50324483 | ||
| Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target. | Q50583627 | ||
| miR-152 regulated glioma cell proliferation and apoptosis via Runx2 mediated by DNMT1. | Q50594880 | ||
| MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma. | Q50894719 | ||
| Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. | Q50933613 | ||
| SAHA-based novel HDAC inhibitor design by core hopping method. | Q51051882 | ||
| Essential Role for Polycomb Group Protein Pcgf6 in Embryonic Stem Cell Maintenance and a Noncanonical Polycomb Repressive Complex 1 (PRC1) Integrity. | Q51219859 | ||
| Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells. | Q52151062 | ||
| DNA methylation in human epigenomes depends on local topology of CpG sites | Q37021507 | ||
| Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry | Q37112417 | ||
| Role of cytosolic NADP+-dependent isocitrate dehydrogenase in ischemia-reperfusion injury in mouse kidney | Q37138815 | ||
| MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells | Q37187706 | ||
| Valproic Acid and Other HDAC Inhibitors Upregulate FGF21 Gene Expression and Promote Process Elongation in Glia by Inhibiting HDAC2 and 3 | Q37220495 | ||
| miR-101 inhibits glioma cell invasion via the downregulation of COX-2. | Q37288437 | ||
| HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity | Q37294988 | ||
| Long Non-coding RNA TUSC7, a Target of miR-23b, Plays Tumor-Suppressing Roles in Human Gliomas | Q37314044 | ||
| Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. | Q37432733 | ||
| Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma | Q37475389 | ||
| Molecular-targeted therapy in malignant melanoma | Q37483949 | ||
| A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies | Q37512730 | ||
| Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. | Q37533362 | ||
| Chromatin Remodeling Factor LSH is Upregulated by the LRP6-GSK3β-E2F1 Axis Linking Reversely with Survival in Gliomas | Q37541852 | ||
| An Insight into the Increasing Role of LncRNAs in the Pathogenesis of Gliomas | Q37670401 | ||
| DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge | Q37729405 | ||
| The DNMT3 family of mammalian de novo DNA methyltransferases | Q37867205 | ||
| Metabolism of glioma and IDH1/IDH2 mutations | Q37925261 | ||
| MicroRNAs in islet immunobiology and transplantation | Q38163421 | ||
| Epigenetic dysregulation in glioma. | Q38213062 | ||
| Assessing MGMT methylation status and its current impact on treatment in glioblastoma. | Q38317424 | ||
| Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. | Q38340158 | ||
| Down-regulation of miR-124 target protein SCP-1 inhibits neuroglioma cell migration | Q38713163 | ||
| Knockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells | Q38720882 | ||
| Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. | Q38725573 | ||
| Mechanism of G9a inhibitor BIX‑01294 acting on U251 glioma cells | Q38737468 | ||
| PTP4A3 is a target for inhibition of cell proliferatin, migration and invasion through Akt/mTOR signaling pathway in glioblastoma under the regulation of miR-137. | Q38763008 | ||
| MiR-153 as a Tumor Suppressor in Glioblastoma Multiforme is Downregulated by DNA Methylation. | Q38769127 | ||
| No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3. | Q38773933 | ||
| MiR-424 functions as a tumor suppressor in glioma cells and is down-regulated by DNA methylation | Q38784189 | ||
| MiR-218 inhibits the tumorgenesis and proliferation of glioma cells by targeting Robo1. | Q38793204 | ||
| miR-373 Inhibits Glioma Cell U251 Migration and Invasion by Down-Regulating CD44 and TGFBR2. | Q38795514 | ||
| Downregulation of miR-195 via cyclosporin A in human glioblastoma cells | Q38822022 | ||
| miR-124 suppresses the migration and invasion of glioma cells in vitro via Capn4. | Q38822348 | ||
| Regulation of IL-8 gene expression in gliomas by microRNA miR-93. | Q38829417 | ||
| The miR-204-3p-targeted IGFBP2 pathway is involved in xanthohumol-induced glioma cell apoptotic death. | Q38834894 | ||
| Overexpression of miR-18a negatively regulates myocyte enhancer factor 2D to increase the permeability of the blood-tumor barrier via Krüppel-like factor 4-mediated downregulation of zonula occluden-1, claudin-5, and occludin | Q38836349 | ||
| MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2. | Q38839310 | ||
| MiR-218 Inhibited Growth and Metabolism of Human Glioblastoma Cells by Directly Targeting E2F2. | Q38870748 | ||
| miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression | Q38876901 | ||
| MiR-221/222 promote human glioma cell invasion and angiogenesis by targeting TIMP2. | Q38904607 | ||
| Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma | Q38912327 | ||
| Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma | Q38916900 | ||
| Inhibition of HDAC increases the senescence induced by natural polyphenols in glioma cells | Q38970906 | ||
| MiR-15b targets cyclin D1 to regulate proliferation and apoptosis in glioma cells | Q38978071 | ||
| MAGED4 expression in glioma and upregulation in glioma cell lines with 5-aza-2'-deoxycytidine treatment | Q38990776 | ||
| Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. | Q39007403 | ||
| miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways | Q39017914 | ||
| PCDH10 is required for the tumorigenicity of glioblastoma cells | Q39035983 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| Post-translational modifications regulate class IIa histone deacetylase (HDAC) function in health and disease | Q28088517 | ||
| The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers | Q28115840 | ||
| Suppression of miR-184 in malignant gliomas upregulates SND1 and promotes tumor aggressiveness | Q28247786 | ||
| Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma | Q28269109 | ||
| De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures | Q28277249 | ||
| Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug | Q28282479 | ||
| RSF governs silent chromatin formation via histone H2Av replacement | Q28472344 | ||
| MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3 | Q28564217 | ||
| Functions of DNA methylation: islands, start sites, gene bodies and beyond | Q29547260 | ||
| Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma | Q29616862 | ||
| Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma | Q30300986 | ||
| miR-873 suppresses H9C2 cardiomyocyte proliferation by targeting GLI1. | Q33292456 | ||
| Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas | Q33361466 | ||
| Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study | Q33383828 | ||
| Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme | Q33387317 | ||
| Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report | Q33390536 | ||
| Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. | Q33402978 | ||
| A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study | Q33406813 | ||
| A mutation in the mouse Chd2 chromatin remodeling enzyme results in a complex renal phenotype | Q33637832 | ||
| Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report | Q33744733 | ||
| Slit2/Robo1 signaling in glioma migration and invasion | Q34152186 | ||
| Chromatin-modifying drugs induce miRNA-153 expression to suppress Irs-2 in glioblastoma cell lines | Q34157966 | ||
| Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region | Q34168829 | ||
| Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma | Q34208293 | ||
| Epigenomic alterations define lethal CIMP-positive ependymomas of infancy | Q34240198 | ||
| Down-regulation of neogenin accelerated glioma progression through promoter Methylation and its overexpression in SHG-44 Induced Apoptosis | Q34292791 | ||
| Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. | Q34352173 | ||
| Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma | Q34381578 | ||
| Novel insights into DNA methylation features in spermatozoa: stability and peculiarities | Q34446771 | ||
| Insulator dysfunction and oncogene activation in IDH mutant gliomas | Q34506441 | ||
| Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation. | Q34511715 | ||
| Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma | Q34544319 | ||
| DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas | Q34645950 | ||
| miR-125b inhibits Connexin43 and promotes glioma growth | Q39094461 | ||
| TFAM is directly regulated by miR-23b in glioma | Q39100619 | ||
| Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells | Q39120070 | ||
| Deletion of the Polycomb-Group Protein EZH2 Leads to Compromised Self-Renewal and Differentiation Defects in Human Embryonic Stem Cells. | Q39123593 | ||
| Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma | Q39154575 | ||
| The Chromatin Assembly Factor Complex 1 (CAF1) and 5-Azacytidine (5-AzaC) Affect Cell Motility in Src-transformed Human Epithelial Cells. | Q39166548 | ||
| Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells | Q39195279 | ||
| MIR-137 suppresses growth and invasion, is downregulated in oligodendroglial tumors and targets CSE1L. | Q39223766 | ||
| MiR-16-1 plays a role in reducing migration and invasion of glioma cells. | Q39240322 | ||
| Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness | Q39266398 | ||
| MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-à-go-go (EAG1). | Q39274181 | ||
| Co-inhibition of microRNA-10b and microRNA-21 exerts synergistic inhibition on the proliferation and invasion of human glioma cells | Q39319105 | ||
| MiR-410 regulates MET to influence the proliferation and invasion of glioma | Q39322020 | ||
| Epigenetic modulation in cancer immunotherapy | Q39369845 | ||
| MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1. | Q39371347 | ||
| miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells | Q39403463 | ||
| Human miR-31 targets radixin and inhibits migration and invasion of glioma cells | Q39442069 | ||
| A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer | Q39450048 | ||
| RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration | Q39472960 | ||
| Knockdown of TFPI-2 promotes migration and invasion of glioma cells | Q39550861 | ||
| Aberrant CpG island hypermethylation and down-regulation of Oct-6 mRNA expression in human hepatocellular carcinoma | Q39568502 | ||
| Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas | Q39600647 | ||
| miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. | Q39613292 | ||
| MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8 | Q39642605 | ||
| Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis | Q39642619 | ||
| MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. | Q39732104 | ||
| Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells | Q39745087 | ||
| Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. | Q39752244 | ||
| Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas | Q39784672 | ||
| Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells | Q39912679 | ||
| Hypermethylation of the RASSF1A gene in gliomas. | Q40477489 | ||
| Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors | Q40621367 | ||
| Methylation of the p73 gene in gliomas | Q40708036 | ||
| NDRG2 and NDRG4 Expression Is Altered in Glioblastoma and Influences Survival in Patients with MGMT-methylated Tumors | Q40853627 | ||
| Regulation of human glioma cell apoptosis and invasion by miR-152-3p through targeting DNMT1 and regulating NF2 : MiR-152-3p regulate glioma cell apoptosis and invasion | Q41206487 | ||
| Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients. | Q41435886 | ||
| Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51 | Q42014579 | ||
| Structure based design, synthesis and activity studies of small hybrid molecules as HDAC and G9a dual inhibitors | Q42064958 | ||
| Blocking of the interaction between Wnt proteins and their co-receptors contributes to the anti-tumor effects of adenovirus-mediated DKK3 in glioblastoma | Q42183976 | ||
| MicroRNA‑21 promotes migration and invasion of glioma cells via activation of Sox2 and β‑catenin signaling. | Q42315668 | ||
| Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy | Q42623558 | ||
| Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02. | Q42696115 | ||
| Assessing the MGMT status in glioblastoma: one step forward, two steps back? | Q43242881 | ||
| MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients | Q44273844 | ||
| The role of DNA methylation in setting up chromatin structure during development | Q44436568 | ||
| Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies | Q44646952 | ||
| Impact of Natural Compounds on DNA Methylation Levels of the Tumor Suppressor Gene RASSF1A in Cancer | Q45814721 | ||
| Growth inhibitory effect on glioma cells of adenovirus-mediated p16/INK4a gene transfer in vitro and in vivo | Q45871582 | ||
| Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy | Q46047090 | ||
| The RNA methyltransferase Dnmt2 methylates DNA in the structural context of a tRNA. | Q46057425 | ||
| A General Non-Radioactive ATPase Assay for Chromatin Remodeling Complexes | Q46196399 | ||
| Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma | Q47151280 | ||
| PRMT5 as a druggable target for glioblastoma therapy. | Q47437818 | ||
| Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical Implications | Q47894744 | ||
| EZH2 Palmitoylation Mediated by ZDHHC5 in p53-Mutant Glioma Drives Malignant Development and Progression | Q47992918 | ||
| Epigenetic inactivation of the hMLH1 gene in progression of gliomas | Q48156262 | ||
| Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression | Q48173093 | ||
| miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1. | Q48189611 | ||
| HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth | Q48227278 | ||
| Associations between TFPI-2 methylation and poor prognosis in glioblastomas | Q48351776 | ||
| 2016 World Health Organization Classification of Central Nervous System Tumors | Q48508591 | ||
| Long non-coding RNA TUG1 acts as a miR-26a sponge in human glioma cells | Q48647907 | ||
| Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors | Q48718306 | ||
| CGCG clinical practice guidelines for the management of adult diffuse gliomas | Q48843889 | ||
| Decreased miRNA-146a in glioblastoma multiforme and regulation of cell proliferation and apoptosis by target Notch1. | Q48877188 | ||
| Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas. | Q48943751 | ||
| Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report | Q34722045 | ||
| Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome | Q34787109 | ||
| MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. | Q34819445 | ||
| Targeting the SMO oncogene by miR-326 inhibits glioma biological behaviors and stemness | Q34886908 | ||
| A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. | Q34977381 | ||
| Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo | Q34979824 | ||
| miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ | Q34988052 | ||
| DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines | Q35098017 | ||
| Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines | Q35209782 | ||
| Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma | Q35252433 | ||
| Upregulation of miR-184 enhances the malignant biological behavior of human glioma cell line A172 by targeting FIH-1. | Q35296213 | ||
| CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells | Q35422357 | ||
| Constitutional tandem duplication of 9q34 that truncates EHMT1 in a child with ganglioglioma | Q35448951 | ||
| Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential | Q35589633 | ||
| A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma | Q35701142 | ||
| MicroRNAome genome: a treasure for cancer diagnosis and therapy. | Q35704188 | ||
| MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion | Q35760644 | ||
| Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma | Q35783190 | ||
| The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma | Q35828522 | ||
| Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines | Q36072085 | ||
| RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas | Q36088188 | ||
| High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma | Q36112656 | ||
| Selective increase in subtelomeric DNA methylation: an epigenetic biomarker for malignant glioma | Q36135415 | ||
| Low MiR-149 expression is associated with unfavorable prognosis and enhanced Akt/mTOR signaling in glioma | Q36261690 | ||
| A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916) | Q36438027 | ||
| miR-128 regulates the apoptosis and proliferation of glioma cells by targeting RhoE | Q36502836 | ||
| Molecular-targeted therapy for elderly patients with advanced non-small cell lung cancer | Q36502935 | ||
| Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1/MLL2 complex recruitment. | Q36606033 | ||
| HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma | Q36694288 | ||
| MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-κB activity | Q36713464 | ||
| MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints | Q36785139 | ||
| Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival. | Q36795811 | ||
| Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas | Q36953248 | ||
| Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth | Q36963419 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | molecular biology | Q7202 |
| P304 | page(s) | 408 | |
| P577 | publication date | 2018-11-15 | |
| P1433 | published in | Frontiers in Molecular Neuroscience | Q27721913 |
| P1476 | title | Potential Epigenetic-Based Therapeutic Targets for Glioma | |
| P478 | volume | 11 |
| Q61814604 | A New Patient-Derived Metastatic Glioblastoma Cell Line: Characterisation and Response to Sodium Selenite Anticancer Agent |
| Q89662426 | Accumulation of DNA methylation alterations in paediatric glioma stem cells following fractionated dose irradiation |
| Q91641073 | Chidamide Inhibits Glioma Cells by Increasing Oxidative Stress via the miRNA-338-5p Regulation of Hedgehog Signaling |
| Q94564068 | Clinical and Biological Significances of a Methyltransferase-Related Signature in Diffuse Glioma |
| Q99635172 | Gut Microbiota and Colon Cancer: A Role for Bacterial Protein Toxins? |
| Q90374346 | HOTAIRM1, an enhancer lncRNA, promotes glioma proliferation by regulating long-range chromatin interactions within HOXA cluster genes |
| Q64083287 | Low LINC00599 expression is a poor prognostic factor in glioma |
| Q90401711 | Specific Glioma Prognostic Subtype Distinctions Based on DNA Methylation Patterns |
| Q90682138 | Systematic Profiling of Alternative mRNA Splicing Signature for Predicting Glioblastoma Prognosis |
Search more.